Skip Navigation


NDT Plus Advance Access originally published online on November 25, 2008
NDT Plus 2009 2(1):52-54; doi:10.1093/ndtplus/sfn180
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/1/52    most recent
sfn180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Selvarajah, V.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool

Viknesh Selvarajah1, Katie Lake1, Sue Robertson1, William Carman2, Chris Isles1 and on behalf of the Scottish Renal Registry

1 Department of Renal Medicine, Dumfries and Galloway Royal Infirmary, Dumfries DG1 4AP
2 West of Scotland Specialist Virology Laboratory, Gartnavel General Hospital, Glasgow G12 0ZA, UK

Correspondence: Correspondence and offprint requests to: Chris Isles, Department of Renal Medicine, Dumfries and Galloway Royal Infirmary, Dumfries DG1 4AP, UK. Tel: +44-1387-241335; Fax: +44-1387-241361; E-mail: chris.isles{at}nhs.net


  Abstract

We report a case of high-grade non-Hodgkin's lymphoma following Epstein-Barr virus (EBV) infection in a 38-year-old renal transplant recipient who was successfully treated with rituximab and remains alive 6 years later with reasonable graft function. We subsequently undertook a survey showing that 1.8% of the Scottish adult transplant pool are susceptible to EBV infection. Though a vaccine for EBV is currently not yet available, routine screening of potential renal transplant recipients for EBV should help identify those at increased risk of post-transplant lymhoproliferative disorder (PTLD), while tailoring of immunosuppression and antiviral prophylaxis with Ganciclovir may help reduce the emergence of this potentially life-threatening disease.

Key Words: EBV • CMV • PTLD • renal • transplantation

Received for publication July 25, 2008. Accepted for publication October 27, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.